Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC - OncLive
Benmelstobart plus anlotinib showed superior PFS (18.96 months vs 9.76 months) and ORR (71.6% vs 25.1%) compared to sunitinib in advanced RCC patients, with a safety profile consistent with each agent.
Related Clinical Trials
Reference News
Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC - OncLive
Benmelstobart plus anlotinib showed superior PFS (18.96 months vs 9.76 months) and ORR (71.6% vs 25.1%) compared to sunitinib in advanced RCC patients, with a safety profile consistent with each agent.
Benmelstobart Combo Improves Outcomes Vs Sunitinib in Advanced RCC - Cancer Network
Benmelstobart plus anlotinib showed improved clinical outcomes for advanced RCC compared to sunitinib in the ETER100 trial, with a median PFS of 18.96 months vs 9.76 months, and ORR of 71.6% vs 25.1%. The combination reduced the risk of progression or death by 47%.